MétaCan
Menu
Back to cohort
Record W2110335058 · doi:10.1016/j.bbmt.2013.10.023

Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission

2013· article· en· W2110335058 on OpenAlexaff
Erica D. Warlick, Kristjan Paulson, Ruta Brazauskas, Xiaobo Zhong, Alan M. Miller, Bruce M. Camitta, Biju George, Bipin N. Savani, Celalettin Üstün, David I. Marks, Edmund K. Waller, Frédéric Baron, César O. Freytes, Gèrard Socié, Görgün Akpek, Harry C. Schouten, Hillard M. Lazarus, Edwin M. Horwitz, John Koreth, Jean‐Yves Cahn, Martin Bornhäuser, Matthew D. Seftel, Mitchell S. Cairo, Mary J. Laughlin, Mitchell Sabloff, Olle Ringdén, Robert Peter Gale, Rammurti T. Kamble, Ravi Vij, Usama Gergis, Vikram Mathews, Wael Saber, Yi‐Bin Chen, Jane L. Liesveld, Corey Cutler, Armin Ghobadi, Geoffrey L. Uy, Mary Eapen, Daniel J. Weisdorf, Mark R. Litzow

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2013
Typearticle
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsOttawa HospitalUniversity of OttawaUniversity of Manitoba
FundersNational Institute of Allergy and Infectious DiseasesNational Cancer InstituteOffice of Naval ResearchNational Heart, Lung, and Blood InstituteTakeda OncologyHealth Resources and Services AdministrationNational Institutes of HealthSwedish Orphan BiovitrumOtsuka AmericaGenentechSeattle GeneticsKiadis PharmaTherakosSigma-Tau PharmaceuticalsMedical College of WisconsinTarix PharmaceuticalsStemCyteBlue Cross and Blue Shield AssociationMerckSpectrum PharmaceuticalsU.S. NavyOsiris TherapeuticsCelgeneNational Center for Advancing Translational SciencesHistoGeneticsTeva Pharmaceutical IndustriesWellPointGlaxoSmithKlineLeukemia and Lymphoma SocietyBe The Match FoundationAllos TherapeuticsAriad PharmaceuticalsOtsuka America PharmaceuticalAmgenSanofiOnyx PharmaceuticalsU.S. Department of DefenseU.S. Department of Health and Human ServicesNational Marrow Donor Program
KeywordsMedicineCytarabineInternal medicineMyeloid leukemiaTransplantationOncologyLeukemiaSurgery

Abstract

fetched live from OpenAlex

The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. We compared transplant outcomes based on exposure to cytarabine postremission consolidation. Three-year survival rates were 36% (95% confidence interval [CI], 29% to 43%) in the no consolidation arm and 42% (95% CI, 37% to 47%) in the cytarabine consolidation arm (P = .16). Disease-free survival was 34% (95% CI, 27% to 41%) and 41% (95% CI, 35% to 46%; P = .15), respectively. Three-year cumulative incidences of relapse were 37% (95% CI, 30% to 44%) and 38% (95% CI, 33% to 43%), respectively (P = .80). Multivariate regression confirmed no effect of consolidation on relapse, disease-free survival, and survival. Before reduced-intensity or nonmyeloablative conditioning HCT, these data suggest pre-HCT consolidation cytarabine does not significantly alter outcomes and support prompt transition to transplant as soon as morphologic CR1 is attained. If HCT is delayed while identifying a donor, our data suggest that consolidation does not increase transplant treatment-related mortality and is reasonable if required.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.288
Teacher spread0.275 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations34
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicAcute Myeloid Leukemia ResearchFrench-language works237,207